Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1011987 | 0.92 | CA1 (0.35) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL83681 | 0.92 | CA1 (0.44) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL1767625 | 0.90 | KDM4E (0.39) | CA1CA2CA4CA9 | |
| SCHEMBL182978 | 0.87 | CA1 (0.35) | CA1CA2CA4CA9 | |
| SCHEMBL308664 | 0.86 | CA1 (0.37) | CA1CA2CA4CA9 | |
| Acetonitrile SCHEMBL28171050 | 0.85 | CA1 (0.40) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL2587081 | 0.84 | CA1 (0.43) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL651045 | 0.84 | CA1 (0.39) | CA1CA2CA4CA9TAAR1 | |
| Sulfuric Acid SCHEMBL28700686 | 0.83 | CA1 (0.46) | CA1CA2CA4CA9TAAR1 | |
| SCHEMBL62392 | 0.83 | CA1 (0.35) | CA1CA2CA4CA9TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039330-A1 | ANIMAL CELL CULTURE MEDIA COMPRISING NON ANIMAL OR PLANT DERIVED NUTRIENTS | Life Technologies Corporation (US) | 2011-02-17 | — | — | US | claimed |
| EP-3492464-B1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-06-02 | — | — | US | disclosed |
| US-10603318-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2020-03-31 | — | — | US | disclosed |
| CN-106117309-B | The inhibitor of Hepatitis C Virus | 吉利德制药有限责任公司 | 2019-08-30 | — | — | CN | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3481823-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2019-05-15 | — | — | EP | disclosed |
| US-20190008858-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2019-01-10 | — | — | US | disclosed |
| EP-3159345-B1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-7259246-B2 | Hybridoma cell line producing monoclonal antibodies to bind to, to detect and qualitatively and quantitatively measure the presence of epitopes of prion proteins; neurodegenerative diseases of the central nervous system | UNIVERSITAT ZURICH (CH) | 2007-08-21 | — | — | US | disclosed |
| US-20060025575-A1 | Hybridoma cell line producing monoclonal antibodies to bind to, to detect and qualitatively and quantitatively measure the presence of epitopes of prion proteins; neurodegenerative diseases of the central nervous system | UNIVERSITAT ZURICH | 2006-02-02 | — | — | US | disclosed |
| EP-1037668-A1 | TRANSFECTION PARTICLES | Boehringer Ingelheim International GmbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| EP-1007700-A1 | IMMUNOLOGICAL DETECTION OF PRIONS | Kanton Zürich vertreten durch Die Erziehungsdirektion (CH) | 2000-06-14 | — | — | EP | disclosed |
| EP-0945138-A1 | Transfection particles | Université Louis Pasteur de Strasbourg (FR) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999029349-A1 | TRANSFECTION PARTICLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1999-06-17 | — | — | WO | disclosed |
| EP-0462009-B1 | Cephalosporins having in position 3 a propenyl radical substituted by a quaternary ammonium, their process for preparation, their use as medicaments, compositions containing them and intermediates | HOECHST MARION ROUSSEL INC (FR) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998037210-A1 | IMMUNOLOGICAL DETECTION OF PRIONS | KANTON ZÜRICH vertreten durch DIE ERZIEHUNGSDIREKTION (CH) | 1998-08-27 | — | — | WO | disclosed |
| EP-0462009-A1 | Cephalosporins having in position 3 a propenyl radical substituted by a quaternary ammonium, their process for preparation, their use as medicaments, compositions containing them and intermediates | ROUSSEL UCLAF (FR) | 1991-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008858-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, GOT1 | CA1 2504/4885CA2 3687/4885CA4 2940/4885 |
| US-10603318-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | CA1 2504/4885CA2 3687/4885CA4 2940/4885 |
| US-10668071-B2 | (Aza)pyridopyrazolopyrimidinones and indazolopyrimidinones and their use | SERPINB6, SERPINC1, SERPINE1 | CA1 3067/4885CA2 4723/4885CA4 4237/4885 |
| US-20110098292-A1 | New Compounds Useful for Treating CNS Disorders | SLC18A2, PMP22, GAP43 | CA1 1430/4885CA2 2299/4885CA4 2403/4885 |
| US-10335409-B2 | Inhibitors of hepatitis C virus | HAVCR2, SLC10A1, GOT1 | CA1 2504/4885CA2 3687/4885CA4 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.